Board Member
Bristol Myers Squibb Co (BMY)Equibles does not estimate personal net worth.
Get an email with a short summary when Bristol Myers Squibb Co publishes a filing, an earnings call transcript or a press release.
Get BMY alertsChristopher Boerner is recorded as Board Member at Bristol Myers Squibb Co (BMY) since May 2, 2023, COO at Bristol Myers Squibb Co (BMY) since April 26, 2023 and CEO at Bristol Myers Squibb Co (BMY). The newest filing on record that lists Christopher Boerner as CEO at Bristol Myers Squibb Co (BMY) is dated March 25, 2026. Bristol Myers Squibb Co reported in an 8-K filed May 4, 2023 that Christopher Boerner was appointed member of the Board, effective May 2, 2023. Bristol Myers Squibb Co reported in an 8-K filed May 4, 2023 that Christopher Boerner was appointed Chief Executive Officer, effective November 1, 2023. Bristol Myers Squibb Co reported in an 8-K filed May 4, 2023 that Christopher Boerner was appointed Chief Operating Officer, effective April 26, 2023. The proxy statement of Bristol Myers Squibb Co reports total compensation of $21,879,919 for Christopher Boerner in fiscal 2025, including a base salary of $1,586,346. Disclosed compensation is on record for 4 fiscal years. Christopher Boerner has spoken on 6 earnings calls across 1 company, most recently for Bristol Myers Squibb Co on October 30, 2025. Bristol Myers Squibb Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Bristol Myers Squibb Co includes Christopher Boerner, Ph.D. (CEO, COO and Board Member), David Elkins (CFO), Sandra Leung (General Counsel) and 5 others.
“On May 2, 2023, the Board elected Dr. Boerner, to serve as a member of the Board, effective May 2, 2023, after the Annual Meeting.”
“On April 26, 2023, Bristol Myers Squibb Company (the "Company") announced that the Board of Directors of the Company ("Board") appointed Christopher Boerner, Ph.D., to serve as the Company's Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.”
“Q3 was another strong quarter, reflecting focused execution across the business as we continue to make progress on our plan to position Bristol-Myers Squibb for long-term sustainable growth.”
“In Q2, we continue to make good progress reshaping the company for long-term sustainable growth. I'm pleased with our performance and our financial results speak to that.”
“We had a strong Q1 driven by solid execution across the business and continued focus on our strategic priorities: maximizing our growth portfolio, accelerating our R&D pipeline, driving operational excellence, and strategically allocating capital.”
“As we'll discuss today, 2024 was a year of good execution across multiple fronts. Importantly, our performance last year establishes a solid foundation to continue our multiyear journey to achieve top-tier sustainable growth by the end of the decade.”
“Q1 was a busy quarter for us and a good start to 2024. Starting on Slide 4, and knowing what an active quarter we had, I wanted to start by telling you how we think about our performance across four dimensions.”
2023-05-02–present
2023-04-26–present
Start not stated–present
Last confirmed March 25, 2026
Proxy statement
Start not stated–2023-03-23
Last confirmed by a filing; no departure on record
Drug Manufacturers - General · Healthcare
CEO, Board Member, COO
2023-04-26–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,586,346 | $21,879,919 |
| 2024 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,536,538 | $18,787,618 |
| 2023 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,256,921 | $8,461,833 |
| 2022 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,064,049 | $6,880,220 |
